HSBC on Biocon
Biocon & partner Mylan launched Ogivri (biosimilar
trastuzumab) in US
Ogivri is well set to grab market share on flexible dosage
offering, supported by co’s robust manufacturing setup
Gaining favourable formulary coverage will be
Buy; TP raise to Rs 325 (Vs Rs 280)